The S-2000 ultrasound scanner, takes shape this week as a new commercial product at the high end of the Siemens Medical Systems’ ultrasound portfolio. The S-2000, cleared by the FDA in mid-October, does not replace the Sequoia, Siemens’ flagship since it acquired ultrasound pioneer Acuson six years ago. Instead, it complements the system, according to Siemens executives, by combining best-of-breed technologies from Sequoia with Siemens’ ultrasound platforms developed prior to the Acuson acquisition.
The S-2000 ultrasound scanner, takes shape this week as a new commercial product at the high end of the Siemens Medical Systems' ultrasound portfolio. The S-2000, cleared by the FDA in mid-October, does not replace the Sequoia, Siemens' flagship since it acquired ultrasound pioneer Acuson six years ago. Instead, it complements the system, according to Siemens executives, by combining best-of-breed technologies from Sequoia with Siemens' ultrasound platforms developed prior to the Acuson acquisition.
The new scanner is the first in the new S-Class of ultrasound systems, which Siemens will position at the top of its ultrasound portfolio. The S-2000 includes an elastographic capability, called Acoustic Radiation Forced Impulse, which the company is framing as the biggest change in the industry since Doppler imaging. This capability, yet to be cleared by the FDA, uses varying acoustic energies to assess tissue stiffness. This may help evaluate abnormalities such as liver tumors or fibrosis. The architecture of the S-2000 system is designed to accommodate a transducer technology in development, Silicon Ultrasound, which promises to enable isotropic 3D imaging over a wide range of applications. The S-2000 will also be able to handle Siemens' pending Automated Breast Scanning, a technique that provides automated, reproducible 3D ultrasound of the breast.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Finds Transvaginal Ultrasound Unreliable for Detecting Endometrial Cancer in Black Patients
July 3rd 2024Utilizing a threshold of less than 5 mm of ultrasound-measured endometrial thickness, the authors of a new study noted an 11.4 percent false-negative probability for endometrial cancer in Black patients.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
FDA Clears Pocket-Sized ECG System and AI Technology for Detection of Cardiac Conditions
June 27th 2024Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.